Nerandomilast (BI 1015550), an oral preferential inhibitor of phosphodiesterase 4B, is being evaluated in two randomized Phase III trials: FIBRONEERTM-IPF (NCT05321069) and FIBRONEERTM-ILD (NCT05321082). Here, PDE4B is linked to interstitial lung disease.